Why is Senores Pharma. falling/rising?

As of 30-Jul, Senores Pharmaceuticals Ltd is currently priced at 695.45, reflecting a decrease of 8.5 points or 1.21%. The stock reached a new 52-week high of Rs 718.2 earlier in the day but has since underperformed its sector by 1.55%. Despite this decline, the stock has shown strong performance over the past week and month, with returns of 13.69% and 19.08%, respectively. The company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 85.60% and operating profit at 130.72%. However, the stock is considered expensive with a price-to-book value of 4.1, and institutional investors have reduced their stakes, indicating potential concerns about its valuation.
In the broader market context, while Senores Pharmaceuticals has outperformed the Sensex over the past week and month, the benchmark has seen a decline of 1.50% and 2.54%, respectively. This suggests that the stock's recent price movement may be influenced by broader market trends, despite its strong individual performance. The decrease in institutional investor participation could also reflect a cautious sentiment among more experienced investors, which may impact the stock's future performance. Overall, while the company has shown positive growth metrics, the combination of high valuation and falling institutional interest may contribute to the current price decline.